2022
Three-Dimensional Quantitative Tumor Response and Survival Analysis of Hepatocellular Carcinoma Patients Who Failed Initial Transarterial Chemoembolization: Repeat or Switch Treatment?
Zhao Y, Haroun R, Sahu S, Schernthaner R, Smolka S, Lin M, Hong K, Georgiades C, Duran R. Three-Dimensional Quantitative Tumor Response and Survival Analysis of Hepatocellular Carcinoma Patients Who Failed Initial Transarterial Chemoembolization: Repeat or Switch Treatment? Cancers 2022, 14: 3615. PMID: 35892874, PMCID: PMC9329887, DOI: 10.3390/cancers14153615.Peer-Reviewed Original ResearchOverall survivalSecond TACEHepatocellular carcinoma patientsFirst TACECarcinoma patientsTumor responseInitial transarterial chemoembolizationMedian overall survivalTransarterial chemoembolization sessionsKaplan-Meier methodLonger overall survivalLog-rank testChemoembolization sessionsConsecutive patientsTransarterial chemoembolizationSurvival outcomesHCC patientsTreatment responseTumor enhancementPatientsSurvival analysisTACEEuropean AssociationRespondersSignificant differences
2014
Transarterial chemoembolization in soft-tissue sarcoma metastases to the liver – The use of imaging biomarkers as predictors of patient survival
Chapiro J, Duran R, Lin M, Mungo B, Schlachter T, Schernthaner R, Gorodetski B, Wang Z, Geschwind JF. Transarterial chemoembolization in soft-tissue sarcoma metastases to the liver – The use of imaging biomarkers as predictors of patient survival. European Journal Of Radiology 2014, 84: 424-430. PMID: 25542065, PMCID: PMC4315698, DOI: 10.1016/j.ejrad.2014.11.034.Peer-Reviewed Original ResearchConceptsMetastatic soft tissue sarcomaProgression-free survivalConventional transarterial chemoembolizationSoft tissue sarcomasOverall survivalTumor responseTransarterial chemoembolizationPatient survivalSafety profileCox proportional hazard ratio analysisProportional hazard ratio analysisSoft tissue sarcoma metastasisMedian overall survivalSalvage therapy optionsHazard ratio analysisReliable clinical dataSize-based criteriaEASL guidelinesModified RECISTIntraarterial therapySarcoma metastasisSurvival outcomesGrade IIIKaplan-MeierTherapy options